HistoryThis section has been translated automatically.
Historical outline and new classification: Knowledge of rare genetic diseases, such as hereditary angioedema (HAE), has rapidly evolved in parallel with the development of new molecular tools. C1 esterase inhibitor (C1-INH) deficiency has been known to be the major cause of HAE (HAE-C1-INH) since the 1960s and has been fundamental to the pathogenetic and pathophysiological understanding of the various angioedemas. These findings led to a dichotomous division of angioedema into acquired histamine-mediated angioedema without C1-INH deficiency and nonhistamine-mediated angioedema. For this group, bradykinin was identified as the crucial causative agent of the edema tendency. This bradykinin group is on the one hand drug-induced (inhibition of the renin-angiotensin system by ACE inhibitors with increased accumulation of bradykinin/frequent occurrence) and on the other hand (rare occurrence) hereditary due to mutations in genes controlling the bradykinin system.
Genetic deficiency of C1-INH is caused by autosomal dominant mutations in the SERPING1 gene, which encodes the C1 esterase inhibitor (C1-INH). The prevalence is 1:50,000. Etiopathogenetically crucial for C1-INH deficiency is the lack of inhibitory effect on the kallikrein-kinin system (plasma kallikrein and factor XIIa) which in turn ultimately leads to an increased bradykinin attack and edema tendency. In HAE type I, C1-INH deficiency is present with decreased plasma levels (C1-INH concentration is in the interval <50% with further decrease with thrust activity). In contrast, in HAE type II, C1-INH is dysfunctional. C1-INH concentration is normal or even elevated, whereas activity is <30% of normal.
In 2000, hereditary angioedema was described for the first time almost exclusively in women with normal C1-INH. This type was designated HAE type III. As a distinctive feature, estrogens (contraceptives, pregnancy, and hormone substitutes) were identified as triggers and potentiators. In 2006, mutations in the F12 gene were first diagnosed in HAE type III.
It later became apparent that HAE type III is not a unitary entity. Thus, in the last three years, advanced next-generation sequencing techniques, in addition to the F12 gene mutation, succeeded in identifying mutations in five other novel genes associated with the hereditary angioedema variants with normal C1-INH (nC1-INH-HAE): ANGPT1 (angiopoietin-1), PLG (plasminogen), KNG1 (kininogen), MYOF (myoferlin), and HS3ST6 (heparan sulfate glucosamine 3-O-sulfotransferase 6).
DefinitionThis section has been translated automatically.
Hereditary angioedema is a rare, genetically heterogeneous inherited disorder characterized by recurrent episodes of fluid accumulation outside the blood vessels, resulting in rapid, potentially life-threatening swelling of tissues in the hands, feet, limbs, face, intestinal tract, or airways.
You might also be interested in
Occurrence/EpidemiologyThis section has been translated automatically.
Incidence: 2-4/100,000 inhabitants/year.
EtiopathogenesisThis section has been translated automatically.
C1-INH belongs to the serpin family of serine esterases and regulates various signal transduction pathways of the complement system, intravascular coagulation, and the contact system of blood coagulation. In the case of HAE, C1-INH deficiency can lead to edema formation in both systems. However, the peptide bradykinin seems to play the central role in the contact system of blood coagulation. Bradykinin causes an increase in nitric oxide, epoprostenol, and endothelium-derived hyperpolarizing factor via its B2 receptor. This results in vasodilation with increased fluid leakage from the vessels and edema formation. At the same time, smooth muscle contractions are induced (cramps and pain). Normally, the release of bradykinin is limited by the action of C1-INH. C1-INH deficiency leads to increased bradykinin release.
- Type I and II: Described as autosomal dominant inheritance with incomplete penetrance of C1 inhibitor gene (C1-INH) mutations located at gene locus 11q12-q13.1. In approximately 80% of cases, there is an inherited C1 esterase inhibitor deficiency, and 20% of patients have a defective C1 esterase inhibitor. Leading symptoms are angioedema of the skin as well as colicky abdominal complaints. In addition to the usual trigger factors, oral contraceptives and pregnancy may also trigger the disease. For all types, surgical procedures (e.g. dental treatment), infections or stress can also trigger relapses.
ManifestationThis section has been translated automatically.
Usually first appearing in childhood, often up to the 5th or later around the age of 15. A third peak of frequency is found in the 3rd decade of life (21-30 years). Rarely beyond the age of 50. No gender preference.
LocalizationThis section has been translated automatically.
Face, extremities (especially arms, more rarely legs), genitals; also lips, tongue, abdomen Life threatening: swelling of the larynx.
Clinical featuresThis section has been translated automatically.
Triggered mostly by minor trauma, infectious diseases involving the oropharynx or menses/pregnancy due to decrease in functionalC1-INH activity.
- Prodromes: Fatigue, headache, malaise, vomiting.
- Integument: Slowly (over hours) developing, localized, skin-colored to markedly faded, nonpruritic, body-warm to cool skin and mucosal edema of variable size and doughy to coarse consistency.
- Regression after hours to 2 days.
- No accompanying urticaria!
- Extracutaneous manifestations: Abdominal colic is characteristic. Misrecognition of clinical symptoms may lead to misdiagnosis and even surgical intervention.
- The development of laryngeal edema is less common than allergy-induced angioedema, but can lead to life-threatening obstruction.
- Direct triggers may include: stress, infections, minor trauma, dental work, menstruation, oral contraceptives (progesterone-only preparations appear to have a beneficial effect on HAE).
LaboratoryThis section has been translated automatically.
Type I: DecreasedC1-esterase inhibitor in blood serum (< 30% of normal), C1-Inh function decreased; decreased total complement or C4.
Type II: High levels of a dysfunctionalC1-esterase inhibitor; C1-INH function decreased (with commercial test systems, substrate conversion can be observed by color change due to lack ofC1-esterase inhibition). C1-INH conc. normal, C4 decreased
DD: nC1-INH-HAE (HAE types III - VIII): NormalC1 and C4. C1-IHF function normal, C1-INH conc normal/slightly elevated; detection of mutations in F-12 (factor XII), ANGPT1 (angiopoietin-1), PLG (plasminogen), KNG1 (kininogen), MYOF (myoferlin), and HS3ST6 (heparan sulfate glucosamine 3-O-sulfotransferase 6).
HistologyThis section has been translated automatically.
Edema in the subcutis. Non-specific pattern.
DiagnosisThis section has been translated automatically.
Laboratory, molecular genetic analysis in patients with a blanched family history.
Hereditary angioedema is suspected when:
- Swelling attacks that develop (slowly) over hours
- C1 inhibitor function/concentration decreased
- No concomitant urticaria
- Painful abdominal colic (pain, nausea, vomiting - CT/ sonography: wall-thickened sections of GI tract, ascites)
- positive family history
- first manifestation between 1-20 years (rarely 20-30 years)
- Prodromi (fatigue, malaise, muscle pain)
- antihistamines are ineffective
- Laryngeal edema (>50% of HAE patients)
- Triggering factors (previous infections, ACE inhibitors, dental treatments, hormonal contraceptives)
Differential diagnosisThis section has been translated automatically.
|Differential diagnostic distinction between "hereditary angioedema" and mast cell mediator-mediated angioedema (as a partial symptom of urticaria).|
|Angioedema (mast cell mediator induced)||hereditary angioedema|
|Pathogenesis||Partial symptom or equivalent of urticaria||Kinin-mediated; by C1-INH deficiency|
|Medical history||No familial clustering; begins in adulthood; often urticaria in the medical history||Mostly familial, usually begins in the 1st or 2nd decade of life; no urticaria in the medical history|
|Trigger||Usually no known triggers, occasionally medication (e.g. aspirin); pressure; vibration||Often spontaneous occurrence; triggering by trauma or psychological stress possible|
|Symptoms||Angioedema mostly periorbital and on the lips; rare or absent gastrointestinal symptoms||Angioedema of the face or extremities; abdominal pain attacks; rarely laryngeal edema; no urticaria|
|Laboratory tests||In general no pathological findings||C1-INH concentration and activity (type 1) as well as C1-INH activity (type II) in plasma reduced|
|Therapy||antihistamines; corticosteroids if necessary||C1-INH concentrate; androgen derivatives, tranexamic acid, Icatibant|
Complication(s)This section has been translated automatically.
TherapyThis section has been translated automatically.
Acute therapy (adults and children):
- C1-INH concentrate: Inject highly purifiedC1-INH concentrate(e.g. Berinert P) 500 IU (10 ml) slowly i.v., in severe cases 1000 IU (20 ml) to max. 10,000 IU. Clinical improvement 20-30 min. after short infusion; check the C4 concentration in the blood as a therapy progress control (increasing). If i.v. therapy is not possible for technical reasons, the preparation can also be effectively administered s.c..
- Icatibant (Firazyr®) is a synthetically produced decapeptide (protein fragment) approved by the EMA for the symptomatic treatment of acute attacks of hereditary angioedema in adults with C1 esterase inhibitor deficiency. This peptide is the most potent antagonist of the bradykinin B2 receptor to date and is available as a pre-filled syringe for subcutaneous injection (recommended dose: 30 mg s.c.). Caution. Inflammatory reactions at the injection site should be noted (redness, swelling, itching, pain).
- Fresh plasma infusions, frozen plasma (500 ml), and lyophilized, clotting-active human plasma.
- Antifibrinolytics: Antifibrinolytics are the second choice (therapeutic success presumably through inhibition of plasmin activation): tranexamic acid (e.g. Ugurol) 1.5-2.0 g/day i.v. or epsilon-aminocaproic acid (e.g. Amicar) 8-10 g/day i.v. under close coagulation control. Complications of these drugs are thromboembolism, myositis and peliosis hepatis.
Drugs not yet approved in Europe:
- Ecallantide: A genetically engineered biopharmaceutical consisting of 60 amino acids, effective as an inhibitor of the enzyme kallikrein. In a clinical trial (EDEMA3) of 36 patients with hereditary angioedema, ecallantide performed better than placebo. Another study of 255 patients is available.
- Rhucin (recombinant C1-INH) is a C1 inhibitor derived from transgenic rabbits by recombinant DNA technology to compensate for C1-INH deficiency (analogous mechanism of action to Berinert). Not approved to date.
- Ecallantide (trade name Kalbitor; highly specific kallikrein inhibitor). Orphan drug designation in Europe.
Long-term therapy (> 1 episode/month; therapy of acute attacks not sufficiently effective/available):
- Lanadelumab (Takhzyro®) is a subcutaneous (every 14 days) recombinant human monoclonal antibody (IgG1-kappa light chain antibody) directed against active kallikrein in blood plasma. The drug has been approved for prophylaxis in patients aged twelve years and older in the EU since 2019.
- Androgens (no approval): In severe course, long-term prophylaxis with stanazol or danazol (e.g. Danadrol; available via international pharmacy) 3 times/day 100 mg (increase up to 600 mg/day possible), after 6 months reduction to 2 times/day 100 mg, after another 6 months alternating 100 and 200 mg/day. Aim for the lowest effective maintenance dose (Milan protocol). Alternatively, start with a low dosage, increase dosage until effective dose is reached (Budapest Protocol). Androgen derivatives promote the expression of male sexual characteristics and lead to masculinization (virilization) of the female organism. There is also a risk of kidney and liver dysfunction. Therefore, close monitoring of the course parameters is necessary. In rare cases, long-term hormone therapy can lead to liver carcinoma. In this respect, this therapy option should be reconsidered. Patients could benefit from a dose reduction or discontinuation of androgen prophylaxis if attacks that occur are controlled with an acute therapy (which can be controlled by the patient) with C1-INH or Icatibant.
- Progestogens: In type III, prophylaxis with progesterone may be successful.
ProphylaxisThis section has been translated automatically.
Berotralstat, Orladeyo®: Oral prophylaxis of HAE for adolescents 12 years and older and adults. 1 time daily 150 mg
Anabolic steroids with androgenic residual potency show good results, e.g. Danazol (e.g. Danazol-ratiopharm Kps.) in an initial dose of 1-3 times/day 1 Kps. à 200 mg p.o. Continuous medication is usually 200 mg/day, possibly further reduction to 2 times/week 50 mg p.o. Caution! Virilisation in women! Long-term prophylaxis is also possible with stanazol. Glucocorticoids and antihistamines usually show no therapeutic efficacy, but are frequently used in the acute phase due to the differential diagnostic difficulties.
Note(s)This section has been translated automatically.
Case report(s)This section has been translated automatically.
Case history 1:
- EA: 31-year-old woman with HAE III. First bulky swellings of face and extremities in LJ 17 with crampy abdominal pain and vomiting. Attacks last about 1-3 days and do not respond to corticosteroids or antihistamines.
- FA: Mother and maternal cousin also suffer from recurrent facial and extremity swelling without response to corticosteroids and antihistamines. Severe attack with laryngeal edema 3 years ago. In recent years recurrences at shorter intervals and with increasing severity.
- Diagnostics: Exclusion of all possible diseases (porphyrins, cryoglobulins, ANA, RF, ACE, histamine in plasma, routine laboratory o.B., no evidence of sensitization against drugs or externals). NormalC1 esterase inhibitor; normal function.
- Tried therapy with danazol 600 mg/day p.o., no further attacks thereafter. Dose reduction at 2-week intervals to 50 mg p.o. 2 times/week as maintenance dose. Pat. has been free of attacks for 2 years!
- Side effects of therapy: weight gain, mild acne papulopustulosa, amenorrhea after cessation of oral contraception, mild hyperandrogenemia.
- One patient showed the following laboratory findings:
- C1-inhibitor protein: 5.6 mg/dL (normal value: 15-35 mg/dL).
- C1-inhibitor function: 1% (normal value 70-130%)
- C4 protein: 10.0 mg/dL (normal value 20-50 mg/dL)
- additional: leukocytosis and elevated CK
- Diagnosis: C1 inhibitor deficiency, presence of hereditary angioedema (type I).
Case report 3:
- A 35-year-old patient comes from a large family in which 10 other members besides him suffer from hereditary angioedema. The first clinical symptoms appeared in him at the age of 27 years. Since then, angioedema had occurred 25 times on the skin, 2 times on the scrotum, and 12 times in the gastrointestinal tract. Gastrointestinal symptoms manifested as colicky pain. The diagnosis was made in 1993. Danazol therapy was refused by the patient. Since 1994, the patient has been treated as an outpatient. Due to severe upper abdominal complaints with repeated vomiting inpatient admission. C1-INH activity: 6%; C1-INH protein: normal, C4: 2mg/dl. Administration of 30 mg Icatibant s.c..30 min later complete regression of pain. 3 hrs later still mild fatigue and some dizziness. After 1 month, acute angioedema of lips and chin region. 2 h later after renewed Icatibant administration (dosage as above) the swelling conditions had largely regressed.
LiteratureThis section has been translated automatically.
- Banerji A et al (2017) Inhibiting Plasma Kallikrein for Hereditary Angioedema Prophylaxis. N Engl J Med 376:717-728.
- Bork K et al (2003) Clinical studies of sudden upper airway obstruction in patients with hereditary angioedema due to C1 esterase inhibitor deficiency. Arch Internal Med 163: 1229-1235
- Bork K et al (2009) Hereditary angioedema caused by missense mutations in the factor XII gene: Clinical features, trigger factors and therapy. J Allergy Clin Immunol 124: 129-134
- Giardino F et al (2015) Use of subcutaneous C1-INH for acute theapy and prophylaxis of a child with HAE. Ped All Immunol 26: 296-297
- Krause K et al (2010) Successful treatment of hereditary angioedema with the bradykinin B2 receptor anatagonist Icatibant. JDDG 8: 272-274
- Magerl M et al (2012) Diagnosis and exclusion of hereditary angioedema. Dermatologist 63: 567-572
- Maurer M et al (2011) Long-term prevention of hereditary angioedema with androgen derivatives: critical evaluation and possible alternatives. JDDG ):99-108
- Nzeako UC et al (2001) Hereditary angioedema a broad review for clinicians. Arch Internal Med 161: 2417-2429
- Nzeako UC et al (2002) Hereditary angioedema as a cause of transient abdominal pain. J Clin Gastroenterol 34: 57-61
- Osler W (1888) Hereditary angioneurotic oedema. On J Med Sci 95: 362-367
- Treudler R (2010) Allergic diseases in pregnant women. dermatologist 61: 1027-1033
- Weiler JM et al (2002) Does heparin prophylaxis prevent exacerbations of hereditary angioedema? J Allergy Clin Immunol 109: 995-1000
Incoming links (14)Anaphylatoxins; Anaphylatoxins; Angioedema acquired; Angioedema hereditary ; Angioedema hereditary type ii; Angioedema hereditary type iii; Angioedema histamine-mediated; C1-esterase inhibitor; C1-esterase inhibitor; Complement system; ... Show all
Outgoing links (13)Angioedema Hereditary 3; Angioedema hereditary 4 ; Angioedema hereditary 6; Angioedema hereditary 7; Angioedema hereditary 8; Angiooedema, hereditary, 5; Bradykinin; Danazol; Ecallantide; Factor xii deficiency; ... Show all
Please ask your physician for a reliable diagnosis. This website is only meant as a reference.